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ABSTRACT
Objectives: To determine chronic opioid use pre-THA
(total hip arthroplasty) and post-THA, and risk factors
for persistent or new chronic opioid use post-THA.
Design: Retrospective cohort study.
Setting: Australian Government Department of
Veterans’ Affairs health claims database.
Participants: 9525 patients who had an elective
unilateral THA between 1/01/2001 and 12/31/2012.
Primary outcome measure: Chronic opioid use.
Defined as 90 days of continuous opioid use or
120 days of non-continuous use.
Results: Pre-THA, 6.2% (n=593) of patients were
chronic users, while 5.2% (n=492) were post-THA.
Among the 492 postoperative chronic users, 302
(61%) were chronic users pre-THA and post-THA and
190 (39%) became new chronic users after surgery.
Risk factors for persistent chronic use were younger
age (OR=0.96, 95% CI 0.93 to 0.99/1-year increment),
back pain (OR=1.99, 95% CI 1.20 to 3.23), diabetes
(OR=3.52, 95% CI 1.05 to 11.8), hypnotics use
(OR=2.52, 95% CI 1.48 to 4.30) and higher pre-THA
opioid exposure (compared with opioid use for 94–
157 days, 157–224 days (OR=3.75, 95% CI 2.28 to
6.18), 225+ days (OR=5.18, 95% CI 2.92 to 9.19).
Risk factors for new chronic opioid use post-THA were
being a woman (OR=1.40, 95% CI 1.00 to 1.96), back
pain (OR=3.90, 95% CI 2.85 to 5.33), depression
(OR=1.70, 95% CI 1.20 to 2.41), gastric acid disease
(OR=1.62, 95% CI 1.16 to 2.25), migraine (OR=5.11,
95% CI 1.08 to 24.18), liver disease (OR=4.33, 95% CI
1.08 to 17.35), weight loss (OR=2.60, 95% CI 1.06 to
6.39), dementia (OR=2.19, 95% CI 1.04 to 4.61),
hyperlipidaemia (OR=1.38, 95% CI 1.00 to 1.91),
hypnotics (OR=1.56, 95% CI 1.13 to 2.16) and
antineuropathic pain medication use (OR=3.11, 95% CI
2.05 to 4.72).
Conclusions: Patients undergoing THA are exposed
to opioids for long periods of time, putting them at
high risk of harm related to opioid use. We identified
groups at risk of chronic opioid use, including younger
patients and women, as well as modifiable risk factors
of chronic opioid use, including level of opioid
exposure presurgery and hypnotic use. These
indicators of chronic opioid use can be used by
clinicians to target patient groups for suitable pain
management interventions.
Strengths and limitations of this study
▪ In a cohort of 9525 patients undergoing total hip
arthroplasties (THAs), we found that 5% of the
patients were chronic opioid users after their
surgery. Of these, 61% were persistent chronic
users (ie, had been chronic opioid users prior to
surgery and continued after surgery), and 39%
became chronic users after surgery.
▪ This study also identified indicators of chronic
opioid use that can be used by clinicians for risk
stratification prior to surgery, and to target
patient groups for suitable pain management
interventions presurgery and postsurgery.
Specifically, back pain, diabetes and preoperative
use of hypnotics were strong risk factors for the
persistent and new development of chronic
opioid use. Additional risk factors for persistent
use included younger age and greater use of
opioids prior to surgery, while for new chronic
use these included being a woman, depression,
migraine, gastric acid disease and antineuro-
pathic pain medications.
▪ The limitations of this study include a conserva-
tive definition of chronic opioid as someone who
was prescribed opioids for 90 consecutive days
or 120 non-consecutive days, and inability to
determine the specific reasons why analgesic
medications were prescribed to patients.
▪ The strengths of this study include a large and
fully captured patient cohort (ie, no missing data
and attrition only related to death), a comprehen-
sive assessment of patient comorbidities using
three comorbidity measures, and the use of
pharmacy data to determine opioid use instead
of patient-reported use which can suffer from
response bias.
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BACKGROUND
Total hip arthroplasty (THA) is the recommended treat-
ment for patients with hip osteoarthritis that have failed
both pharmacological and non-pharmacological treat-
ment for the severe pain, and limited function caused
by their condition.1 THA is the fourth most common
surgical procedure in the USA, with 468 000 performed
in 20122; it is one of the top 20 most common surgical
procedures in Australia, with 26 000 performed in 2013.3
THA is considered a clinically effective, successful oper-
ation with reported cost-effectiveness.1 However, while
joint-related pain is expected to be resolved after surgi-
cal rehabilitation, there is a high prevalence of patients
who report persistent chronic pain and some patients
who report chronic pain development subsequent to the
procedure.4
Chronic and persistent pain post-THA occurs in
7–23% of patients.4 5 One study reported moderate-
to-severe hip pain after primary THA in 8% of patients.6
Other studies suggested that 3–25% of patients take
opioid medications for almost 5 years after their
surgery.6 7 There are several reasons that suggest the use
of opioids in patients with THA is high, and abuse of
these medications could affect these patients. First, it is
well established that the use of opioids has increased
worldwide for all non-cancer chronic pain manage-
ment.8–11 In the treatment of musculoskeletal pain,
opioids use increased by 50% between 2006 and 2010,12
and surgeons are reportedly some of the highest prescri-
bers of these medications.13 Second, as opioids are
recommended for the treatment of osteoarthritis1 and
surgical recovery,14 patients undergoing THA are likely
to be exposed to opioids for long periods of time,
increasing their chance of developing tolerance, hyper-
algesia,15 and other dangerous and potentially costly
opioid-related side effects.16 Third, the comorbidity
burden of patients undergoing THA has increased in
the past two decades,17–19 suggesting that patients can,
and are likely to, be suffering from other types of pain
and taking opioids for these other conditions, which
also affect their surgical outcomes.20 Finally, in addition
to the high exposure to these medications, there is the
potential of adverse events associated with opioid use in
surgical recovery.14 The higher medical complexity of
the patients undergoing THA creates potential interac-
tions between these opioid medications and the speciﬁc
surgical outcomes of the procedure. Currently it is not
well understood how opioids are used in this patient
population and who is at risk of harm.
Understanding who is at risk of persistent chronic
opioid use and developing new chronic use in this
patient population can be useful to the surgeons, the
patients themselves and the general healthcare system of
which they are a part. Our study was conducted to iden-
tify patients at a high risk of chronic opioid use who may
beneﬁt from targeted interventions for better pain man-
agement strategies and opioid use education.
Speciﬁcally, the purpose of this study was to (1)
determine the prevalence of chronic opioid use before
and after THA surgery, and (2) determine the character-
istics associated with persistent chronic opioid use or
becoming a new chronic user after surgery.
METHODS
Study design, setting and study sample
A retrospective cohort study was conducted. Patients
who underwent a THA procedure between 1/01/2001
and 12/31/2012 were included in the study. The study
cohort comprised of patients who received care subsi-
dised by the Australian Government Department of
Veterans’ Affairs (DVA). The DVA administrative claims
database, which includes detailed information on all
inpatient hospitalisations, prescription medications,
medical procedures and allied health services provided
to veterans, was used for the study. The DVA’s client ﬁle,
which contains information on gender, date of birth,
date of death and family status for a treatment popula-
tion of 242 000 veterans and spouses in September 2011,
was also used. In the prescription data set, medications
are coded according to the WHO anatomic, therapeutic
and chemical classiﬁcation (ATC),21 and the Australian
Pharmaceutical Beneﬁts Schedule (PBS) item codes.22
In the inpatient hospitalisation data set, encounters are
coded using the International Classiﬁcation of Diseases,
10th Revision, Australian Modiﬁcation (ICD-10-AM)
codes.23
Patients older than 18 years of age were selected for
the study if they underwent elective unilateral THA
(identiﬁed using ICD-10-AM procedure code 4 931 800),
did not have other hip or knee arthroplasties within
1 year of the index THA, and did not have history of
cancer (ICD-10-AM C00.x–C26.x, C30.x–C34.x, C37.x–
C41.x, C43.x, C45.x–C58.x, C60.x–C76.x, C81.x–C85.x,
C88.x,C90.x–C97.x, C77.x–C80.x, C81.x–C85.x, C88.x,
C96.x, C90.0, C90.2 and antineoplastic and immunomo-
dulating agents medication history ATC codes L01*).
The cohort was initially comprised of 10018 THAs
belonging to 9373 patients. Of these, 493 THAs were
not included in the ﬁnal sample as they either experi-
enced a revision (N=202) or died (N=290) within a year
of surgery or did not have complete 1-year follow-up
(N=1). Patients with revisions or who died within 1 year
were excluded to reduce the effect these events could
have on the amount of opioids a patient would take;
thus, an accurate description of chronic opioid use
could be determined. The ﬁnal cohort comprised 9525
THAs given to 8925 patients (8325 patients had one
THA and 600 had two surgeries more than 1 year
apart).
Outcomes of interest
Chronic opioid use after surgery was the main outcome
of interest. Chronic opioid use was deﬁned as having
any number of opioid prescriptions or dosing for at least
90 days continuously, or opioid prescriptions for 120
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non-consecutive days.24 The number of days was
obtained from the number of units supplied. No gap
days between one prescription supply and another were
allowed when determining consecutive prescription of
opioids. New chronic users were those who did not have
chronic use prior to their THA. Persistent chronic
opioid users were those with chronic opioid use before
and after surgery.
Opioids (ATC code=N02A*, inclusive of opioid-like
medications such as Tramadol) 365 days pre-THA
(admission date) and post-THA (discharge date) were
extracted from the DVA prescription database, and the
number of dispensed prescriptions and the days of
expected utilisation were calculated. Dosages were con-
verted to oral morphine equivalents (OMEs),25 and the
daily OMEs were summed across the days within the
pre-THA and post-THA periods to estimate the total
OME for these time periods. When determining
whether patients were chronic opioid users post-THA,
the immediate 90-day period after THA was excluded as
the use of opioids in this period is related to surgical
recovery and rehabilitation. Therefore, each patient had
275 potential days of medication utilisation post-THA.
To obtain a similar exposure period preoperatively, we
excluded the 90-day period between 365 and 275 days
prior surgery. Patients were assigned to the opioid use
categories of ‘chronic’, ‘some’ and ‘none’ opioid use for
the periods of pre-THA and post-THA. After classifying
chronic users, the remaining opioid users were classiﬁed
as ‘some’ opioid use if they did not ﬁt the chronic cri-
teria, and those without any opioid dispensing were
assigned to the ‘none’ category.
Risk factors
Age, sex, surgical indication, bilaterality, opioid-related
comorbidities, other medical comorbidities and other
analgesic medication were evaluated as risk factors of
persistent or new chronic opioid use after surgery.
Comorbidities were identiﬁed using a combination of
the RxRisk-V, Elixhauser and Charlson measures.26 27
Using these three comorbidity measures provided a
comprehensive ascertainment of conditions because it
used both medication dispensing history and hospital
encounters of the patients in the year prior to their
surgery. The opioid-related comorbidities investigated
included depression, back pain, anxiety, psychoses,
alcohol abuse, bipolar disorder and drug abuse. The 49
medical comorbidities investigated, which included car-
diovascular and blood, endocrine, gastrointestinal, mus-
culoskeletal, neurological, nutritional, renal, respiratory,
and other body systems, can be seen in table 1.
Additional analgesic medication evaluated included non-
steroids anti-inﬂammatories (ATC code=M01A*), muscle
relaxants (ATC code=M03*), antineuropathic pain medi-
cations (ATC codes=N06AA09, N06AX21, N03AX12,
N03AX16),28 hypnotics (ATC code=N05C*, inclusive of
sedatives) and corticosteroids (ATC codes=H02AA*,
H02AB*). Since the comorbidities of pain treated with
opioids, pain treated with anti-inﬂammatory medications
and steroid-responsive disorders were identiﬁed using
only the RxRisk-V medication comorbidity measure we
did not include them in our ﬁnal analyses, as these are
likely to be highly correlated to the other analgesic
medication evaluated. Days of opioid use (per quartile
of days) and average daily use were investigated as risk
factors for persistent chronic opioid use.
Statistical analyses
Frequencies, proportions, medians, IQR, means and SD
described the study sample. The prevalence of opioid
use, as well as crude overall mean OME taken and days
of opioid use per subgroup were calculated. The
adjusted change in mean OME and mean days of opioid
use from pre-THA to post-THA were calculated using
generalised linear models. Logistic regression models
were used to identify risk factors associated with persist-
ent chronic opioid use and new chronic opioid use after
surgery. In both models, all candidate covariates were
modelled in a bivariate model with the outcome of inter-
est. If their association with the outcome had a p<0.2,
then these were included in the subsequent multivari-
able model. Collinearity between the variables in ﬁnal
models was evaluated, and tolerance values were >0.1 in
all cases. ORs and 95% CIs are provided. All tests were
two-sided, and α=0.05 was considered statistically signiﬁ-
cant. SAS V.9.4 (SAS Institute, Cary, North Carolina,
USA) was used for all analyses.
Sensitivity analysis
High and long-term use of non-steroidal anti-inﬂammatory
drugs are risk factors for gastric acid disease, a condition
treated with proton-pump inhibitors;29 30 therefore, we
tested this interaction in a sensitivity analysis—no inter-
action was found and data are not shown.
Patient involvement
No patients were involved in the design of this study, in
developing the outcome measures nor in the conduct of
the study. There are no plans to disseminate the results
to study participants.
RESULTS
Our cohort of 9525 primary THAs was 51.3% (n=4891)
women and had a median age of 80 years (5th–95th
centile 76–84 years) at the time of surgery. Table 1
describes patients’ characteristics, comorbidities and
other analgesic medication use pre-THA and post-THA
as per their pre-THA chronic opioid use status.
Presurgery, 6.2% (n=593) of patients were considered
chronic opioid users, while 5.2% (n=492) were users
postsurgery. Of the 492 chronic users post-THA, 61.4%
(n=302) were persistent chronic users (chronic users
pre-THA and post-THA) and 38.6% (n=190) became
chronic users after surgery (ie, 38 were considered
‘none’ and 152 were considered ‘some’ users pre-THA).
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Table 1 Descriptive characteristics of the total hip arthroplasty study cohort
Characteristic All None Some Chronic
Total, n (%) 9525 5138 (53.9) 3794 (39.8) 593 (6.2)
Age at surgery, median (5th–95th centile), years 80 (76–84) 81 (63–88) 80 (61–89) 81 (59–89)
Sex, n (%)
Women 4891 (51.3) 2558 (49.8) 1977 (52.1) 356 (60.0)
Men 4634 (48.7) 2580 (50.2) 1817 (47.9) 237 (40.0)
Bilateral (more than 365 days), n (%) 1200 (12.6) 669 (13.0) 473 (12.5) 58 (9.8)
Year of operation, n (%)
2001–2002 1738 (18.2) 1001 (19.5) 694 (18.3) 43 (7.3)
2003–2004 1840 (19.3) 980 (19.1) 786 (20.7) 74 (12.5)
2005–2006 1654 (17.4) 925 (18.0) 651 (17.2) 78 (13.2)
2007–2008 1590 (16.7) 853 (16.6) 612 (16.1) 125 (21.1)
2009–2010 1454 (15.3) 750 (14.6) 572 (15.1) 132 (22.3)
2011–2012 1249 (13.1) 629 (12.2) 479 (12.6) 141 (23.8)
Surgical indication, n (%)
ICD-10-AM M161: other primary osteoarthritis 7826 (82.2) 4241 (82.5) 3092 (81.5) 493 (83.1)
ICD-10-AM M169: osteoarthritis unspecified 882 (9.3) 513 (10.0) 342 (9.0) 27 (4.6)
Other 817 (8.6) 384 (7.5) 360 (9.5) 73 (12.3)
Opioid-related comorbidities
Depression, n (%) 1695 (17.8) 755 (14.7) 764 (20.1) 176 (29.7)
Back pain, n (%) 1367 (14.4) 466 (9.1) 694 (18.3) 207 (34.9)
Anxiety, n (%) 1167 (12.3) 445 (8.7) 569 (15.0) 153 (25.8)
Psychoses, n (%) 191 (2.0) 96 (1.9) 74 (2.0) 21 (3.5)
Alcohol abuse, n (%) 88 (0.9) 36 (0.7) 45 (1.2) 7 (1.2)
Bipolar disorder, n (%) 26 (0.3) 14 (0.3) 11 (0.3) 1 (0.2)
Drug abuse, n (%) 11 (0.1) 4 (0.1) 3 (0.1) 4 (0.7)
Cardiovascular/blood comorbidities
Hypertension, n (%) 5384 (56.5) 2789 (54.3) 2215 (58.4) 380 (64.1)
Anticoagulation agents/coagulopathy, n (%) 5071 (53.2) 2676 (52.1) 2077 (54.7) 318 (53.6)
Hyperlipidaemia, n (%) 3621 (38.0) 1819 (35.4) 1534 (40.4) 268 (45.2)
IHD hypertension, n (%) 3341 (35.1) 1722 (33.5) 1392 (36.7) 227 (38.3)
Antiplatelet agents, n (%) 3213 (33.7) 1594 (31.0) 1377 (36.3) 242 (40.8)
Arrhythmias, n (%) 1837 (19.3) 937 (18.2) 774 (20.4) 126 (21.2)
Congestive heart failure, n (%) 1277 (13.4) 556 (10.8) 585 (15.4) 136 (22.9)
Angina, n (%) 1112 (11.7) 484 (9.4) 530 (14.0) 98 (16.5)
Myocardial infarction, n (%) 241 (2.5) 112 (2.2) 112 (3.0) 17 (2.9)
Peripheral vascular disease, n (%) 225 (2.4) 105 (2.0) 100 (2.6) 20 (3.4)
Valvular disease, n (%) 225 (2.4) 118 (2.3) 96 (2.5) 11 (1.9)
Cerebrovascular disorders, n (%) 201 (2.1) 90 (1.8) 95 (2.5) 16 (2.7)
Pulmonary circulation disorders, n (%) 109 (1.1) 54 (1.1) 42 (1.1) 13 (2.2)
Endocrine comorbidities
Diabetes uncomplicated, n (%) 1007 (10.6) 474 (9.2) 440 (11.6) 93 (15.7)
Hypothyroidism, n (%) 674 (7.1) 348 (6.8) 260 (6.9) 66 (11.1)
Diabetes with complications, n (%) 624 (6.6) 284 (5.5) 281 (7.4) 59 (9.9)
Pancreatic insufficiency, n (%) 15 (0.2) 4 (0.1) 10 (0.3) 1 (0.2)
Gastrointestinal comorbidities
Gastric acid disorder, n (%) 4267 (44.8) 1981 (38.6) 1904 (50.2) 382 (64.4)
Liver disease (severe) or failure, n (%) 361 (3.8) 121 (2.4) 173 (4.6) 67 (11.3)
Peptic ulcer disease, n (%) 95 (1.0) 47 (0.9) 40 (1.1) 8 (1.3)
Inflammatory bowel syndrome, n (%) 80 (0.8) 40 (0.8) 37 (1.0) 3 (0.5)
Liver disease (mild), n (%) 25 (0.3) 9 (0.2) 13 (0.3) 3 (0.5)
Hepatitis C, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Musculoskeletal/pain-related comorbidities
Osteoporosis/Paget’s, n (%) 1189 (12.5) 564 (11.0) 496 (13.1) 129 (21.8)
Gout, n (%) 950 (10.0) 471 (9.2) 407 (10.7) 72 (12.1)
RA/collage vascular disorders, n (%) 108 (1.1) 32 (0.6) 62 (1.6) 14 (2.4)
Migraine, n (%) 28 (0.3) 9 (0.2) 11 (0.3) 8 (1.3)
Continued
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On average, a chronic opioid user before surgery had
55.5 (95% CI 51.4 to 59.7) OMEs mg/day and was dis-
pensed opioids for 189.9 (95% CI 185.69 to 193.9) days.
Postsurgery they had 57.5 (95% CI 52.1 to 62.8) OMEs
mg/day and were dispensed opioids for 193.0 (95% CI
188.8 to 197.1) days. See table 2 for prevalence of opioid
use type, daily OMEs and average number of days for
each group, as well as changes in the group pre-THA
and post-THA.
Risk factors for persistent chronic opioid use were
younger age (OR=0.96, 95% CI 0.93 to 0.99/1-year
increment), presence of back pain (OR=1.99, 95% CI
1.20 to 3.23), uncomplicated diabetes (OR=3.52, 95%
CI 1.05 to 11.8) and use of hypnotics pre-THA
(OR=2.52, 95% CI 1.48 to 4.30). The number of days
on opioids prior to surgery was associated with odds of
continuing to be a chronic opioid user after surgery
after 94 days using opioids. Compared with opioid use
for 94–157 days, patients who used opioids for 157–
224 days had a 3.75 (95% CI 2.28 to 6.18) higher odds
of being a persistent user, and those who used it for
225+ days had a 5.18 (95% CI 2.92 to 9.19) higher
odds (table 3).
Risk factors for patients to develop chronic opioid
use after THA were being a woman (OR=1.40, 95% CI
1.00 to 1.96), presence of back pain (OR=3.90, 95% CI
Table 1 Continued
Characteristic All None Some Chronic
Neurological comorbidities
Dementia, n (%) 191 (2.0) 97 (1.9) 65 (1.7) 29 (4.9)
Epilepsy 421 (4.4) 143 (2.8) 210 (5.5) 68 (11.5)
Parkinson’s disease, n (%) 152 (1.6) 62 (1.2) 70 (1.8) 20 (3.4)
Other neurological disorders, n (%) 119 (1.2) 60 (1.2) 47 (1.2) 12 (2.0)
Paralysis (or paraplegia/hemiplegia), n (%) 63 (0.7) 26 (0.5) 32 (0.8) 5 (0.8)
Nutritional/obesity comorbidities
Deficiency anaemia, n (%) 152 (1.6) 65 (1.3) 72 (1.9) 15 (2.5)
Obesity, n (%) 146 (1.5) 57 (1.1) 77 (2.0) 12 (2.0)
Weight loss, n (%) 87 (0.9) 31 (0.6) 49 (1.3) 7 (1.2)
Blood loss anaemia, n (%) 60 (0.6) 24 (0.5) 29 (0.8) 7 (1.2)
Malnutrition, n (%) 16 (0.2) 9 (0.2) 5 (0.1) 2 (0.3)
Hyperkalaemia, n (%) 3 (0.0) 3 (0.1) 0 (0.0) 0 (0.0)
Renal/urological
Renal disease/failure, n (%) 410 (4.3) 168 (3.3) 196 (5.2) 46 (7.8)
Benign prostatic hypertrophy, n (%) 352 (3.7) 189 (3.7) 137 (3.6) 26 (4.4)
Respiratory comorbidities
Reactive airway disease, n (%) 1978 (20.8) 931 (18.1) 888 (23.4) 159 (26.8)
Chronic pulmonary disease, n (%) 504 (5.3) 230 (4.5) 228 (6.0) 46 (7.8)
Tuberculosis, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Miscellaneous comorbidities
Allergies, n (%) 1327 (13.9) 592 (11.5) 618 (16.3) 117 (19.7)
Glaucoma, n (%) 897 (9.4) 494 (9.6) 356 (9.4) 47 (7.9)
Smoking, n (%) 90 (0.9) 32 (0.6) 53 (1.4) 5 (0.8)
Psoriasis, n (%) 46 (0.5) 19 (0.4) 24 (0.6) 3 (0.5)
Transplant, n (%) 2 (0.0) 1 (0.0) 1 (0.0) 0 (0.0)
HIV, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other analgesic medication use
Pre-THA
NSAIDs, n (%) 6093 (64.0) 3007 (58.5) 2722 (71.7) 364 (61.4)
Hypnotics and sedatives, n (%) 1904 (20.0) 693 (13.5) 1012 (26.7) 199 (33.6)
Corticosteroids, n (%) 1275 (13.4) 474 (9.2) 672 (17.7) 129 (21.8)
Antineuropathic pain, n (%) 657 (6.9) 205 (4.0) 333 (8.8) 119 (20.1)
Muscle relaxants, n (%) 27 (0.3) 7 (0.1) 17 (0.4) 3 (0.5)
Post-THA
NSAIDs, n (%) 4288 (45.0) 2033 (39.6) 1969 (51.9) 286 (48.2)
Hypnotics and sedatives, n (%) 1950 (20.5) 762 (14.8) 982 (25.9) 206 (34.7)
Corticosteroids, n (%) 1242 (13.0) 497 (9.7) 623 (16.4) 122 (20.6)
Antineuropathic pain, n (%) 678 (7.1) 233 (4.5) 326 (8.6) 119 (20.1)
Muscle relaxants, n (%) 24 (0.3) 5 (0.1) 15 (0.4) 4 (0.7)
Overall and by preoperative opioid utilisation status, 2001–2012.
ICD-10-AM, International Classification of Diseases, 10th Revision, Australian Modification; NSAID, non-steroidal anti-inflammatory drugs; RA,
rheumatoid arthritis; THA, total hip arthroplasty.
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2.85 to 5.33), depression (OR=1.70, 95% CI 1.20 to
2.41), migraine (OR=5.30, 95% CI 1.12 to 25.01), liver
disease (mild; OR=4.33, 95% CI 1.08 to 17.35), weight
loss (OR=2.60, 95% CI 1.06 to 6.39), dementia
(OR=2.19, 95% CI 1.06 to 6.39), gastric acid disease
(OR=1.62, 95% CI 1.16 to 2.25), hyperlipidaemia
(OR=1.38, 95% CI 1.00 to 1.91), and preoperative use
of hypnotics (OR=1.56, 95% CI 1.13 to 2.16) and anti-
neuropathic pain medication (OR=3.11, 95% CI 2.05 to
4.72; table 4).
Table 2 Prevalence of opioid use, mean daily oral morphine equivalents use, and days of use pre-THA and post-THA by
opioid user status, and change in daily use and days by pre-THA to post-THA status
Opioid use post-THA Opioid use pre-THA
Total None Some Chronic
Prevalence, n (%)
Total 9525 5138 (5339) 3794 (39.8) 593 (6.2)
None 6626 (69.6) 4369 (85.0) 2146 (56.6) 111 (18.7)
Some 2407 (25.3) 731 (14.2) 1496 (39.4) 180 (30.4)
Chronic 492 (5.2) 38 (0.7) 152 (4.0) 302 (50.9)
Daily OME use for group and change in daily OME use,* mg, mean (95% CI)
Total 0.0 (0.0 to 0.0) 38.3 (37.6 to 39.0) 55.5 (51.4 to 59.7)
None 0.0 (0.0 to 0.0) 0.0 (−0.1 to 0.1) −37.7 (−38.4 to −37.0) −55.3 (−59.4 to −51.2)
Some 37.5 (36.6 to 38.4) 36.6 (35.7 to 37.5) −1.1 (−2.1 to −0.1) −18.7 (−22.9 to −14.5)
Chronic 57.5 (52.1 to 62.8) 56.2 (51.2 to 61.2) 18.6 (13.6 to 23.6) 0.9 (−3.2 to 5.0)
Days using opioids for group and change in days use,* mean (95% CI)
Total 0.0 (0.0 to 0.0) 27.0 (26.1 to 27.9) 189.9 (185.9 to 193.9)
None 0.0 (0.0 to 0.0) −0.2 (−0.3 to −0.1) −25.9 (−26.8 to −25.0) −187.0 (−190.9 to −183.1)
Some 24.4 (23.3 to 25.5) 22.7 (21.6 to 23.8) −3.0 (−4.3 to −1.7) −164.0 (−168.1 to −159.9)
Chronic 193.0 (188.8 to 197.1) 189.0 (184.8 to 193.2) 163.3 (159.1 to 167.5) 2.6 (−2.3 to 7.5)
*Adjusted for age, sex, surgical indication, bilateral status, RxRisk-V comorbidity burden, back pain, year of operation, and prior THA and
post-THA other analgesic medication use.
OME, oral morphine equivalents; THA, total hip arthroplasty.
Table 3 Risk factors of persistent chronic opioid use after THA in patients who were chronic user presurgery (N=302/593)
Risk factor Crude OR (95% CI) p Value Adjusted OR (95% CI) p Value
Demographics
Age (per 10-year increment) 0.97 (0.95 to 0.98) <0.001 0.96 (0.93 to 0.99) <0.001*
Opioid-related comorbidities
Back pain 1.69 (1.20 to 2.38) 0.003 1.99 (1.20 to 3.23) 0.008*
Depression 1.60 (1.12 to 2.28) 0.009 1.14 (0.67 to 1.96) 0.629
Psychoses 1.97 (0.78 to 4.96) 0.149 1.47 (0.39 to 5.42) 0.563
Medical comorbidities
Diabetes with complications 2.19 (1.12 to 3.87) 0.007 3.52 (1.05 to 11.8) 0.042*
IHD hypertension 0.80 (0.58 to 1.12) 0.199 0.66 (0.41 to 1.07) 0.090
Diabetes uncomplicated 2.17 (1.36 to 3.45) 0.001 1.89 (0.78 to 4.57) 0.160
Liver disease (severe) or failure 1.49 (0.89 to 2.50) 0.129 1.25 (0.59 to 2.66) 0.566
Migraine 2.93 (0.59 to 14.6) 0.190 1.76 (0.18 to 17.3) 0.628
Hypertension 1.28 (0.92 to 1.79) 0.147 0.98 (0.59 to 1.63) 0.934
RA/collage vascular disorders 2.46 (0.76 to 7.92) 0.133 1.01 (0.25 to 4.71) 0.925
Analgesic use
Days using opioids prior to surgery <0.001 <0.001
<94 –† –†
94–156 Ref Ref
157–224 3.75 (2.28 to 6.18) 3.63 (2.08 to 6.34)
225+ 4.85 (2.89 to 8.15) 5.18 (2.92 to 9.19)
Average daily use of opioids (per 10 OME increment) 1.11 (1.06 to 1.15) 1.06 (1.00 to 1.11) 0.065
Pre-THA: hypnotics and sedatives 1.72 (1.21 to 2.42) 0.002 2.52 (1.48 to 4.30) <0.001*
*Significant variables (p<0.05) in final model.
†No cases of persistent chronic users in this group, could not model this level.
IHD, ischaemic heart disease; OME, oral morphine equivalents; RA, rheumatoid arthritis; Ref, reference; THA, total hip arthroplasty.
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DISCUSSION
In this large cohort of patients who had undergone
THAs, we determined that 6.2% of patients were
chronic opioid users before surgery, and 5.2% were
chronic opioid users after surgery. After THA, 61.4% of
the chronic users of opioid had been chronic users
before surgery, and 38.6% of them were new chronic
users postsurgery. After evaluating patient characteristics,
56 patient comorbidities and other analgesic medica-
tion, we identiﬁed several risk factors associated with
chronic opioid use.
Both sex and age were associated with chronic opioid
use. Being female was associated with a 40% higher risk
of developing chronic opioid use after surgery.
Identifying women at a higher risk of chronic use in a
THA population is consistent with studies that evaluated
different aspects of the sex and pain relationship.
Speciﬁcally, women are at a higher risk of acute pain
after THA surgery,31 as well as persistent and chronic
postoperative pain;32 therefore, women had higher
general utilisation of opioids in the long term.6 7 We
also found that chronic opioid users were younger.
While this was not a risk factor for development of new
chronic opioid use post-THA, it was a risk factor for
persistent chronic use or not reducing use after
surgery. There is some evidence that younger patients
are at a higher risk of persistent opioid use in the
general surgical population.33 It has also been sug-
gested that younger patients utilise higher perioperative
opioid amounts.34 This higher utilisation is reported
Table 4 Risk factors for developing new chronic opioid use after THA surgery (N=190/8932)
Risk factor Crude OR (95% CI) p Value Adjusted OR (95% CI) p Value
Demographics
Sex: women vs men 1.47 (1.09 to 1.97) 0.011 1.40 (1.00 to 1.96) 0.049*
Opioid-related comorbidities
Back pain 5.52 (4.12 to 7.41) <0.001 3.90 (2.85 to 5.33) <0.001*
Depression 2.13 (1.56 to 2.93) <0.001 1.70 (1.20 to 2.41) 0.003*
Alcohol abuse 3.08 (1.23 to 7.71) 0.016 2.16 (0.75 to 6.22) 0.152
Psychoses 2.98 (1.55 to 5.74) 0.001 1.39 (0.65 to 2.96) 0.392
Anxiety 1.66 (1.14 to 2.43) 0.009 1.00 (0.66 to 1.50) 0.990
Medical comorbidities
Migraine 5.16 (1.19 to 22.38) 0.028 5.11 (1.08 to 24.18) 0.040*
Liver mild disease 7.37 (2.16 to 25.10) 0.001 4.33 (1.08 to 17.35) 0.039*
Weight loss 3.82 (1.64 to 8.89) 0.002 2.60 (1.06 to 6.39) 0.038*
Dementia 2.79 (1.40 to 5.56) 0.003 2.19 (1.04 to 4.61) 0.039*
Gastric acid disease 2.49 (1.84 to 3.36) <0.001 1.62 (1.16 to 2.25) 0.004*
Hyperlipidaemia 1.76 (1.32 to 2.34) <0.001 1.38 (1.00 to 1.91) 0.048*
Diabetes with complications 2.08 (1.34 to 3.25) 0.001 1.86 (0.97 to 3.57) 0.063
Epilepsy 3.15 (1.97 to 5.02) <0.001 1.01 (0.58 to 1.77) 0.972
Benign prostatic hypertrophy 1.64 (0.89 to 3.05) 0.116 1.61 (0.81 to 3.22) 0.176
Peripheral vascular disease 2.44 (1.27 to 4.68) 0.008 1.57 (0.77 to 3.19) 0.215
Osteoporosis/Paget’s 1.89 (1.32 to 2.71) 0.001 1.30 (0.88 to 1.93) 0.186
Myocardial infarction 2.46 (1.32 to 4.59) 0.005 1.46 (0.73 to 2.94) 0.284
Diabetes uncomplicated 1.40 (0.92 to 2.13) 0.114 0.76 (0.41 to 1.39) 0.374
Antiplatelets agents 1.38 (1.03 to 1.85) 0.032 0.85 (0.61 to 1.17) 0.317
Chronic pulmonary disease 2.10 (1.30 to 3.41) 0.003 1.31 (0.74 to 2.33) 0.349
Reactive airway disease 1.33 (0.96 to 1.85) 0.091 0.89 (0.60 to 1.30) 0.538
Hypothyroidism 1.63 (1.02 to 2.61) 0.042 1.22 (0.74 to 2.00) 0.442
Angina 1.86 (1.28 to 2.68) 0.001 1.18 (0.77 to 1.79) 0.446
RA/collage vascular disorders 2.63 (1.06 to 6.54) 0.038 1.38 (0.49 to 3.84) 0.542
Inflammatory bowel syndrome 2.55 (0.92 to 7.06) 0.071 1.37 (0.45 to 4.17) 0.583
Liver disease (severe) or failure 2.21 (1.24 to 3.93) 0.007 1.10 (0.59 to 2.04) 0.764
Congestive heart failure 1.85 (1.30 to 2.64) 0.001 1.07 (0.72 to 1.60) 0.728
Parkinson’s disease 2.23 (0.97 to 5.12) 0.059 1.14 (0.43 to 3.01) 0.796
Renal disease/failure 1.91 (1.10 to 3.32) 0.022 1.06 (0.59 to 1.91) 0.849
Other neurological disorder 2.29 (0.92 to 5.68) 0.074 1.14 (0.38 to 3.44) 0.811
Other analgesic use
Pre-THA: hypnotics and sedatives 2.31 (1.70 to 3.12) <0.001 1.56 (1.13 to 2.16) 0.007*
Pre-THA: antineuropathic pain 4.72 (3.31 to 6.72) <0.001 3.11 (2.05 to 4.72) <0.001*
Pre-THA: muscle relaxants 4.22 (0.87 to 18.06) 0.053 1.95 (0.39 to 9.74) 0.416
Pre-THA: corticosteroids 1.78 (1.25 to 2.55) 0.002 1.17 (0.79 to 1.74) 0.430
Bilateral procedure (more than 365 days) 0.60 (0.36 to 1.00) 0.049 0.70 (0.41 to 1.20) 0.194
*Significant variables (p<0.05) in final model.
RA, rheumatoid arthritis; THA, total hip arthroplasty.
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even without consistent evidence that younger patients
experience greater pain from the procedure; for
example, Liu et al31 reported higher scores for
moderate-to-severe pain in younger patients, but Petre
et al34 did not.
There are several opioid-related comorbidities asso-
ciated with higher risk of chronic opioid use in our
cohort. Back pain was the condition most consistently
associated with chronic opioid use. Patients with back
pain, diagnosed prior to surgery, were four times more
likely to develop chronic opioid use if they did not
already have it, and two times more likely to continue
their chronic use after surgery. In the general popula-
tion, back pain is one of the strongest predictors for
opioid abuse,35 and its association with the pain and util-
isation of opioids in a THA population7 is expectedly
strong.20 Another condition commonly associated with
high opioid utilisation and abuse, which was also found
in our study, was depression.36 Depression was risk factor
for new chronic opioid use. This has been reported in at
least two other THA cohorts, one which assessed depres-
sion using patient medication assessments and one via a
patient-reported questionnaire.31 37
One of the strongest general medical comorbidities
risk factor for new opioid chronic use was pre-THA
migraine, a condition associated with chronic pain and
one where opioids are recommended for pain treat-
ment.38 Liver disease was also strongly associated with
new chronic opioid use, conﬁrming previously reported
associations in non-THA cohorts.39 Dementia, a moder-
ate risk factor for new chronic use, was reportedly asso-
ciated with chronic opioid use in general cohorts of
patients, but to our knowledge, this is the ﬁrst time it is
reported in a THA cohort.40 The dispensing of
proton-pump inhibitors was used to identify patients suf-
fering from gastric acid disorder, a condition present in
44% of our cohort. We found this condition to be
weakly associated with new chronic use development,
which to our knowledge has also not been previously
reported. We did not assess the duration of
proton-pump inhibitors use. While the majority of
people who took these medications did not become
chronic opioid users, long-term use of proton-pump
inhibitors has been shown to increase the risk of bone
fracture41 and surgical site infections,42 events that if
present or developing after surgery could lead to the
development of chronic opioid use after surgery. Weight
loss, a moderate risk factor for new chronic use, and
hyperlipidaemia, a borderline risk factor for chronic
opioid use, were identiﬁed, but to our knowledge such
associations have not been previously evaluated and we
cannot, therefore, make comparisons. Finally, some
established risk factors for chronic opioid use, including
psychiatric comorbidities, alcohol and substance abuse,
were not observed in our study. It is likely that these
comorbidities were either well managed in these
patients or the higher risk of opioid abuse in them was
recognised and properly managed by their providers.
Diabetes was a moderate risk factor for persistent
opioid use in this study. This has also been reported in
other major elective surgical procedures33 and corrobo-
rates a recent report of it being associated with persist-
ent pain post-THA.5 Rajamäki et al5 suggested that
either the constant chronic inﬂammation state that
patients with diabetes are in or diabetic-related compli-
cations, such as neuropathy, could be associated with
the mechanism to explain opioid use in patients with
THA.
Prior opioid and adjuvant analgesics usage were also
associated with risk of persistent or new chronic opioid
use. The greater the number of days someone was dis-
pensed opioids prior to surgery was associated with a
higher likelihood of continuing to be a chronic user,
which is consistent with studies reporting that the
greater exposure to opioids, the greater the risk of
abuse.43 Use of other medications, such tricyclic antide-
pressants and anticonvulsants, recommended for neuro-
pathic pain, was also associated with a higher risk of
persistent and new chronic use; this again conﬁrms ﬁnd-
ings from general major elective surgical populations.33
Our study could not determine whether opioid use
was associated with pain in the index joint. While we
believe that opioid use is an efﬁcient proxy for pain
assessment measurement in joint replacement patients,
as it identiﬁes someone who has been prescribed a
medication that is only recommended for refractory
pain management,1 we understand that measuring and
evaluating pain is difﬁcult and more complex than only
using opioid prescriptions.44 We also could not identify
the reasons for the other analgesic medication patients
were taking during the study timeline. It is possible they
were prescribed these medications for reasons other
than the joint pain. Additionally, our observational study
used prescriptions to measure opioid use in this cohort
of patients; therefore, we do not know whether patients
were compliant to medication instructions.
Our study limitations include the conservative deﬁn-
ition of chronic opioid user as someone who was pre-
scribed opioids for 90 consecutive days or 120
non-consecutive days, which could miss the identiﬁca-
tion of opioid abuse (ie, overdoses or poisoning earlier
on) in this patient population. We tried to include as
many comorbidities, including those like migraine that
is considered to be a chronic pain condition, in our ana-
lysis, but it is still possible that other chronic pain condi-
tions, such as ﬁbromyalgia, can be present and not
accounted for in our analysis, both as a possible risk
factor and as a confounder of the other relationships
studied. Other confounding variables that we were
unable to assess, such as body mass index, psychological
well-being, function status, prescribers’ preferences, as
well as information regarding the index surgery, such as
intraoperative complications, anaesthesia, length of stay
and discharge destination, could affect the relationship
between the risk factors we identiﬁed for persistent or
new chronic use of opioid. Also, it is possible that due to
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the relatively low proportion of patients with some of
the risk factors assessed, we may have been underpow-
ered to detect associations between these factors and the
likelihood of chronic or persistent opioid use. Finally,
our study was comprised of an older cohort of
Australian patients, making our results possibly less gen-
eralisable to a younger joint-replacement population.
The strengths of our study include our large patient
cohort, which allowed for robust estimates on various
risk factors. In an attempt to provide the most compre-
hensive assessment of patient comorbidities, we used
three comorbidity measures to identify conditions using
both inpatient hospitalisations and medication history.
Our use of pharmacy data to determine opioid use,
which provided us with more detailed information on
the medication used by the study cohort, was less subject
to recall bias than other studies that relied on patient or
surgeon-reported measurements. Finally, the DVA
administrative data used in this study covers all services
provided to the Australian veteran population, assuring
that we had complete data on all the procedures, hospi-
talisations and medications provided to these patients.
This guaranteed to our study a low risk of missing data
and attrition in the cohort.
CONCLUSION
Of the 492 (5% of the total cohort) chronic opioid
users after THA, 61% were persistent chronic users and
39% became chronic users after surgery. Back pain, dia-
betes and preoperative use of hypnotics were strong risk
factors for the persistent and new development of
chronic opioid use. Additional risk factors for persistent
use included younger age and longer use of opioids
prior to surgery, while for new chronic use these
included being a woman, depression, migraine, gastric
acid disease and antineuropathic pain medications.
These indicators of chronic opioid use can be used by
clinicians for risk stratiﬁcation prior to THA surgery,
and will help to target patient groups for suitable pain
management interventions presurgery and postsurgery.
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